Dr. Alvaro Macieira-Coelho is a Research Director at the French National Institute of Health. He received an MD from the University of Lisbon, Portugal, and a PhD from the University of Uppsala Sweden. He made an internship at the University Hospital in Lisbon and was a research associate at the Wistar Institute in Philadelphia (USA) and at the Department of Cell Biology of the University of Uppsala (Sweden). He became Head of the Department of Cell Pathology at the Cancer Institute in Villejuif (France) and was a visiting Professor at the University of Linkoping (Sweden). He published 150 papers in professional Journals and 9 books on cancer and aging. He received the following awards: Fritz Verzar Prize (University of Vienna, Austria), “Seeds of Science”, Career Prize (Lisbon, Portugal), Dr. Honoris Causa (University of Linkoping, Sweden), Johananof International Visiting Professor (Institute Mario Negri, Milano, Italy).

Cancer Research, Cell Biology, Cancer and Aging, Molecular Biology

Liane Deligdisch graduated Medical School in Bucharest, Romania. Following positions were: Gynecologist and General Physician in Romania until 1963, Pathologist at the Ichilov Hospital, Tel Aviv Medical School, Israel 1963 to 1975, Visiting Professor Magee Women Hospital in Pittsburgh, Pa.; 1975-6 Boston Free Hospital for Women, Harvard Medical School ; 1976 to present The Mount Sinai School of Medicine, full Professor of Pathology and Obstetrics-Gynecology and Attending since 1986. Founded the division of Gynecologic Pathology and directed the course of Gynecologic Pathology at the Medical School, Authored 143 peer reviewed articles , 7 textbooks on Gynecologic Pathology.

Gynecology, Obstetrics-Gynecology, Gynecologic Pathology

Dr. Sherry Bradford attended undergraduate school at SUNY at Buffalo and was awarded a full tuition scholarship to pursue her PhD graduate degree (Biochemistry) from the University of Buffalo/ Roswell Park Cancer Institute Division of SUNY at Buffalo School of Medical and Biomedical Sciences. During her clinical laboratory vocation, she was solicited by the Chief of Surgery at Millard Fillmore Hospital, Buffalo, NY, to direct the Surgical Research laboratory. There she successfully led the research on the use of human micro vascular umbilical cord endothelium for lining stents. It was while Sherry was at Millard Fillmore Hospital, that she was awarded the “1st Place - Award for Excellence in Research” from the American Federation for Clinical Research In 1997, Dr. Bradford was approached by the Department of Pharmacokinetics, at Millard Fillmore Hospital, to lead their newly formed Pharmacokinetics Oncology Department. As the Principal Investigator, she was charged with the responsibility to develop an in vitro chemo sensitivity test on tumor cells using the flow cytometer. In 2008, Dr Bradford and colleagues form AccuTheranostics and the idea on Oncology Personalized Medicine based on the specific patient’s own biochemical and genetic profile to administer Personalized treatment regimens.Currently, Dr. Bradford sits on the EDITORIAL BOARD of the International Journal of Medical and Health Sciences Research; commence on July 20 2014; and on the EDITORIAL BOARD of Insights in Cancer Research, and has authored and co-authored a number of scientific peer-reviewed manuscripts.She is also a member of many professional organizations including (but not limited to): International Metabolic Cancer Group, AACR, ASCO, and GLIFCA.

Research interest includes human microvascular umbilical cord endothelium and in Pharmacokinetics Oncology

Oliver Micke has completed his PhD at the age of 25 years from Muenster University Hospital in 2006. He is head of the Head of the department for radiotherapy and radiation oncology at the Franziskus Hospital Bielefeld since 2006. In addition he is the medical director of Franziskus Hospital Bielefeld, a premier teaching hospital of the Medical University of Hanover (MHH). He has published more than 200 papers in reputed national and international journals and has been serving as reviewer as well as an editorial board member of repute.

Radiotherapy, Radiation Oncology

ORONZO BRUNETTI graduated cum laude in 2008 from the University of Bari School of Medicine, Bari, Italy. Since graduation, he has become involved in studies on translational research in solid tumors. Since 2014, he is a member of AIOM (the Italian Association of Medical Oncology). Since 2015, he is a member of the Italian Group for Diagnosis and Treatment of Biliary Cancer (GICO). From 2016 he has been involved in the elaboration of guidelines of exocrine pancreatic carcinoma for the AIOM.

Identification of prognostic/predictive biomarkers in pancreatic, biliary, and hepatocellular cancer.